首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Clinical Breast Cancer

Clinical Breast Cancer杂志,由Elsevier出版,于2000年创刊,Bimonthly,出版语言English,ISSN:1526-8209,E-ISSN:1938-0666。

投稿咨询
Clinical Breast Cancer
Clinical Breast Cancer
Clinical Breast Cancer
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
3区
影响因子
2.7
CiteScore
4.9
期刊收录
SCI、SCIE

Clinical Breast Cancer(中文译名:《临床乳腺癌》),ISSN:1526-8209,EISSN:1938-0666,是Elsevier出版的国际性学术期刊,创刊于2000年,以Bimonthly形式稳定发行,2026年总发文量约188篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.7,2025年期刊CiteScore为4.9,2025年期刊自引率约3.7%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Clinical Breast Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约3月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、Canada、Japan、South Korea、England等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF TEXAS SYSTEM、PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PCSHE)、DANA-FARBER CANCER INSTITUTE、UNICANCER、MAYO CLINIC等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 185 / 333

44.6

学科:ONCOLOGY SCIE Q3 202 / 333

39.49

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 188 / 328

42.8

学科:ONCOLOGY SCIE Q3 174 / 328

47.1


中国学者近期发文

1
The Role of Primary Tumor Surgery in Oligometastatic Breast Cancer: A Meta-Analysis of Randomized and Observational Studie

Author:Zhang, Ziteng; Ma, Xiaoxuan; Zhang, Jing; Zhao, Yuanyuan; Guo, Wei; Liu, Yunjiang; Yang, Chao

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 5, pp. 1-10. DOI: 10.1016/j.clbc.2026.03.003

2
From Bitter Taste Perception to Anti-Cancer Weapons: New Directions for Bitter Taste Receptors in Malignant Tumor Treatmen

Author:Wei, Tao; Liu, Shaojun; Xu, Ting; Liu, Min

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 5, pp. 46-56. DOI: 10.1016/j.clbc.2026.03.009

3
Multidimensional Regulatory Mechanisms of Extracellular Matrix Stiffness in Breast Cancer and Its Prospects for Clinical Translatio

Author:Lin, Meixiao; Jiang, Yemei; Chen, Yaofeng; Yang, Hua; Xun, Yang

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 4, pp. 85-97. DOI: 10.1016/j.clbc.2026.02.017

4
Impact of Post-Neoadjuvant Chemotherapy Biomarker Changes on Long-Term Oncological Outcomes in Non-pCR Breast Cance

Author:Lu, Yige; Yuan, Quan; Yu, Hao; Li, Xiaoming; Sha, Yupeng; Zhu, Yingze; Niu, Ming; Pang, Hui

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 4, pp. 144-149. DOI: 10.1016/j.clbc.2026.02.006

5
Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Treatment De-Escalatio

Author:Li, Hongbo; Wang, Zhiyong

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 4, pp. 150-157. DOI: 10.1016/j.clbc.2026.02.012

6
The Pedicled Lateral Thoracic Lymph-Adipofascial Flap: A Nonmicrosurgical Lymph-Interpositional Technique to Prevent Upper Limb Lymphedema After Axillary Lymph Node Dissection-Preliminary Outcome

Author:Wu, Jiannan; Bao, Haoshi; He, Zhou; Xing, Yue; Deng, Heran

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 4, pp. 1-7. DOI: 10.1016/j.clbc.2026.02.001

7
Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysi

Author:Au, Lok-Sze Joyce; Zhang, Yu-ning; Yeung, Kary; Cheung, Ka-Long; Hou, Li-Yu Holly; Luk, Mai-Yee; Leung, Ching-Yu Roland; Chan, Wing-Lok

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 3, pp. 84-93. DOI: 10.1016/j.clbc.2026.01.007

8
A Venous Thromboembolism-Associated Model for Predicting Tumor Microenvironment Features in Breast Cance

Author:Liu, Zhuoyun; Guo, Shuang; Xu, Xianqun; Tang, Peng; Xue, Han; Long, Xinghua

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 3, pp. 102-118. DOI: 10.1016/j.clbc.2026.01.011

9
Comment on: Prognostic Ability of the Indication for Adjuvant Systemic Therapy Based on Preoperative Biopsy and the Surgical Excision Specimen in Cases of Small Breast Tumors (CONSCIENCE): A Retrospective Cohort Stud

Author:Zhu, Xuezheng; Liao, Daquan; Huang, Shiye; Feng, Yubin; Zhuang, Ziye

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 3, pp. 198-199. DOI: 10.1016/j.clbc.2025.10.007

10
Overall Survival and Related Clinicopathologic Features to Identify Low-Risk Patients With Early Breast Cancer Suitable For Radiation Therapy Omission After Conservative Surgery: A Meta-Analysi

Author:Zhi, Ouyang; Li, Songlian; Quan, Ai

Journal: CLINICAL BREAST CANCER. 2026; Vol. 26, Issue 3, pp. 154-168. DOI: 10.1016/j.clbc.2025.10.002


在线咨询

Clinical Breast Cancer

国际简称:CLIN BREAST CANCER参考译名:临床乳腺癌

年发文量:188 CiteScore:4.9 是否预警:否 Gold OA文章占比:14.34% 研究类文章占比:84.57%

杂志社联系方式:CIG MEDIA GROUP, LP, 3500 MAPLE AVENUE, STE 750, DALLAS, USA, TX, 75219-3931

Clinical Breast Cancer